Skip to main content

Table 3 RAS mutation prevalence estimates for tumour samples tested for all RAS codons

From: RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres

  

RAS mutation status

RAS mutation prevalence

 

Variable (n)

Criterion

Wild-type

Mutated

(%)

95 % CI

P-value

Overall RAS mutation prevalence (n = 2,245)

Patients with all codons tested only

1,156

1,089

48.5

(46.4–50.6)

 

Location of primary tumoura (n = 1,393)

Right colon (proximal to splenic flexure)

232

279

54.6

(50.2–59.0)

 

Left colon (distal to splenic flexure)

230

199

46.4

(41.6–51.2)

0.012b

Rectum

222

231

51.0

(46.3–55.7)

0.043c

Tissue type isolateda (n = 1,669)

Primary tumour

651

653

50.1

(47.3–52.8)

 

Metastatic site

184

181

49.6

(44.3–54.8)

0.869

Number of patients tested per year (n = 2,093)

>80

861

850

49.7

(47.3–52.0)

 

≤80

295

239

44.8

(40.5–49.0)

<0.001

Indication for testing (n = 2,215)

“On request from an oncologist”

1,019

964

48.6

(46.4–50.8)

 

“All patients with CRC tested”

33

51

60.7

(49.5–71.2)

 

“Other”

84

64

43.2

(35.1–51.6)

0.036d

Location of testing (n = 2,245)

Own institution

1,117

1,054

48.5

(46.4–50.7)

 

Own institution and external

39

35

47.3

(35.6–59.3)

0.832

Minimum percentage of neoplastic cells (n = 2,445)

No cut-off defined

75

78

51.0

(42.8–59.1)

 

Cut-off defined

1,081

1,011

48.3

(46.2–50.5)

0.526

Cut-off percentage of neoplastic cells (n = 2,092)

Cut-off <10 %

177

137

43.6

(38.1–49.3)

 

Cut-off ≥10 %

904

874

49.2

(46.8–51.5)

0.071

DNA extraction method used (n = 2,245)

QIAamp DNA FFPE kit (Qiagen)

475

463

49.4

(46.1–52.6)

 

Cobas DNA Sample Preparation kit (Roche)

75

73

49.3

(41.0–57.7)

 

QIAamp DNA mini kit (Qiagen)

79

56

41.5

(33.1–50.3)

 

Raw proteinase K lysate

97

79

44.9

(37.4–52.6)

 

Maxwell 16 (Promega)

192

178

48.1

(42.9–53.3)

 

MagNAPure (Roche)

15

19

55.9

(37.9–72.8)

 

Other

223

221

49.8

(45.0–54.5)

0.550

  1. aOnly includes wild-type and mutated results. Patients with unknown/unavailable RAS mutation status have been excluded
  2. bComparison of RAS mutation prevalence between right colon and left colon primary tumours only, excluding data from rectal tumours
  3. cComparison of RAS mutation prevalence between right colon, left colon and rectal primary tumours
  4. dFor the purposes of comparing RAS mutation prevalence, patients reported as having been tested due to “Other” indications have been grouped together
  5. Of note, patients reported in aggregated data sample may have had RAS-family mutations affecting more than one oncogene
  6. CRC colorectal cancer, CI confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us